Compare Cytokinetics Inc (CYTK) vs Ecolab Inc. (ECL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Ecolab Inc. — how do they compare? Cytokinetics Inc trades at $76.43 (market cap $10.63B), while Ecolab Inc. trades at $280.9 (market cap $79.79B). The key difference: Ecolab Inc. is far larger — about 7.5× Cytokinetics Inc's market cap, and Ecolab Inc. pays a 1.03% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | ECL | |
|---|---|---|
Market Cap | $10.63B | $79.79B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $308.35 |
52-Week Low | $34.31 | $245.73 |
Enterprise Value | $10.74B | $88.57B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
ECL trades at $284.4, down slightly (-0.27%) on the day, with a bullish technical signal and strong analyst support (78% buy ratings). The company reported solid Q2 2026 earnings of $2.09 per share, beating estimates, and raised full-year guidance. Revenue growth is steady, with 2025 revenue at $16.08B, and profitability remains robust with a net income margin of 12.57%. Recent news highlights institutional activity and the completion of the $4.75B CoolIT acquisition, strengthening its high-tech portfolio.
The outlook is positive, driven by earnings momentum, strategic acquisitions, and a consensus price target of $327.90 implying ~15% upside. Key risks include execution of integration for recent acquisitions, input cost pressures, and broader market volatility. The stock presents a compelling opportunity for growth investors seeking exposure to a stable, dividend-paying company with digital and high-tech expansion drivers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
